Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1127173

registered interest
date	16/05/2019
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	Development Aid: Climate Change
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Development, pursuant to the Answer of 16 April 2019 to Question HL15044 on Developing Countries: Climate Change, how much of the £5.8 billion allocated to international climate finance between 2016-17 and 2020-21 will be spent on tackling loss and damage in climate-vulnerable countries.
tabling member constituency	Liverpool, Walton
tabling member printed	Dan Carden
uin	255379
answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>Action to avert, minimize and address loss and damage associated with climate change is intricately bound up with action on mitigation, adaptation, disaster risk reduction and disaster preparedness and response. We therefore do not see that attempting to define a separate category of finance for loss and damage as useful or practical. Of the £5.8bn on climate finance we have committed to spend from 2016-2021 the UK aims to spend 50% on adaptation and 50% on mitigation.</p> answering member constituency Penrith and The Border answering member printed Rory Stewart question first answered 21/05/2019 16:48:42 answering member 4137 label Biography information for Rory Stewart
tabling member	4651 label Biography information for Dan Carden

1127214

registered interest
date	16/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies, if the Government will withdraw its support for suggested amendments to remove every mention of high prices.
tabling member constituency	Liverpool, Walton
tabling member printed	Dan Carden
uin	255380
answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p> </p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 255381 255382 question first answered 21/05/2019 16:12:54 answering member 4455 label Biography information for Seema Kennedy
tabling member	4651 label Biography information for Dan Carden

1127215

registered interest
date	16/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies, if the Government will take steps to help ensure that the recommendation to member states calls for mandatory rather than voluntary measures.
tabling member constituency	Liverpool, Walton
tabling member printed	Dan Carden
uin	255381
answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p> </p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 255380 255382 question first answered 21/05/2019 16:12:54 answering member 4455 label Biography information for Seema Kennedy
tabling member	4651 label Biography information for Dan Carden

1127216

registered interest
date	16/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if the Government will support the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies.
tabling member constituency	Liverpool, Walton
tabling member printed	Dan Carden
uin	255382
answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p> </p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 255380 255381 question first answered 21/05/2019 16:12:54 answering member 4455 label Biography information for Seema Kennedy
tabling member	4651 label Biography information for Dan Carden

1127289

registered interest
date	16/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the affordability of medicines as a result of the redrafted WHO resolution entitled, Improving the transparency of markets for medicines, vaccines and other health-related technologies proposed by Italy on 29 April 2019.
tabling member constituency	Liverpool, Walton
tabling member printed	Dan Carden
uin	255695
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:32:11 answering member 4455 label Biography information for Seema Kennedy
tabling member	4651 label Biography information for Dan Carden